Cadrenal Therapeutics, Inc.
CVKD
$10.63
$1.7719.98%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -11.54% | -53.25% | -131.19% | -265.99% | -132.30% |
| Total Depreciation and Amortization | 0.00% | -20.00% | 816.67% | -33.33% | -33.33% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 57.85% | 207.05% | 237.52% | 640.25% | 95.76% |
| Change in Net Operating Assets | -54.96% | -92.78% | -303.72% | 372.10% | -136.76% |
| Cash from Operations | -7.09% | -97.87% | -153.15% | -157.88% | -250.62% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -58.19% | -- | 685,066.67% | -- | -74.86% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 66.98% | -- | -- | -- | -- |
| Cash from Financing | -57.56% | -- | 656,600.00% | 59,710.40% | -76.52% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -154.06% | -15.44% | -46.07% | 899.83% | -111.45% |